Moderna Inc. (MRNA) rallied 178% on Tuesday after its experimental mRNA-based cancer vaccine demonstrated a statistically significant improvement in progression-free survival for melanoma patients in a Phase 3 trial. The milestone, though limited to a specific patient cohort, triggered a sharp short-covering rally that pushed the stock to $174.38, well above its estimated fair value of $57.43.
The surge contrasted with the company’s latest financial results. For the second quarter of 2026, Moderna reported a net loss of $782 million, with a negative net income margin of -145.2% and an EBITDA margin of -147.1%. Earnings per share came in at -$1.96, reflecting continued pressure from declining COVID-19 vaccine revenues. Over the past year, the stock has surged 548.5%, driven largely by speculative momentum rather than sustained profitability.
Peer biotech firms posted markedly different performance metrics. Amgen Inc. (AMGN) reported a Q2 2026 EPS of $4.40 with a net income margin of 21.0%, while AbbVie Inc. (ABBV) posted EPS of $2.04 and a net income margin of 6.9%. Vertex Pharmaceuticals Incorporated (VRTX) delivered EPS of $4.34 with a 32.9% net income margin. Moderna’s realized 30-day volatility reached 348.7%, far exceeding the 27.7% to 32.0% range observed among its peers.
The cancer vaccine breakthrough, though clinically significant, does not represent a universal cancer cure and remains in early commercialization stages. Analysts caution that the stock’s valuation—at 5.16 times sales—appears disconnected from current revenue streams, which continue to rely heavily on pandemic-era products. The company has not provided updated guidance for the fiscal year 2025.
